Clinical Trial Search

Primary: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months — 28; 22 Participants

Primary: Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero — 35.5; 46.8; 11.8 Percentage of Patients

Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters

Primary: Number of Eyes With Inflammation Recurrence — 1 eye with inflammation

Primary: Number of Participants With Absence of Intraocular Inflammation at 6 Months — 12 Participants

Primary: Number of Participants With Adverse Events — 398; 101 participants

Primary: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography — 3; 1; 1 Participants

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Time to Treatment Failure on or After Week 2 — 8.3; NA; 5.6; NA months — p=0.004

Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants

Primary: The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5 — 28; 44; 27 Participants

Primary: Adverse Events — 27; 1 Participants

Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001

Primary: Inflammation Grade at Day 7 — 0.625; 1.444 units on a scale

Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…

Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…

Primary: Number of Participants With Response Rate for the Individual Response Criteria - in the Study Eye — 3; 3; 0; 1 Participants

Primary: Evaluation of Safety and Tolerability by Determining Treatment Emergent Adverse Events — 12 Participants

Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants

Primary: The Utilization of the Mk II Inserter From the Day of Treatment Through 7 Days Following Treatment. — 10; 3; 3; 2 Eyes

Primary: Proportion of Subjects With Recurrence of Uveitis in the Study Eye and Overall Summary of Number of Participants With Ocular Treatment-Emergent Adverse Events for the…

Primary: Anterior Chamber Cell Grade at Week 8 — -0.7; -0.9; -0.5 units on a scale

Primary: Number of Participants With Systemic Toxicities, Adverse Events, or Infections — 6 Participants

Primary: Assessment of Both Systemic and Ocular Adverse Events — 2; 5 Participants

Primary: Meibomian Gland Secretion Quality — 1.7; 1.7; 1.8 Units on a scale

Primary: Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following…

Primary: Corticosteroid-sparing Treatment Success Within the First 6 Months After Randomization — 0.69; 0.54 Cumulative proportion of participants — p=0.029

Primary: Time to Treatment Failure on or After Week 6 — 3.0; 5.6; 3.0; 4.8 months — p=<0.001

Primary: Anterior Chamber Cell (ACC) Grade = 0 on Day 28 — 38; 32; 44; 15 Participants

Primary: Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16 — 30.0; 46.1 Percentage of participants — p=0.2354